Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
- Participation in prestigious conference can boost company's reputation
- None.
To learn more about Quanterix, visit www.quanterix.com/company/ To learn more about Quanterix’s Simoa® technology, visit: www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905628089/en/
Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations Contact:
Ed Joyce
610-306-9917
ir@quanterix.com
Source: Quanterix Corporation
